The GBA Multimodal Study in Parkinson's Disease
Recruiting now
Conditions studied: Parkinson Disease, GBA Gene Mutation, Gaucher Disease
In brief
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.
Key facts
- Study ID
- NCT04101968
- Run by
- Pacific Parkinson's Research Centre
- People needed
- 25
- Starts
- 2019-05-01
- Expected to finish
- 2025-12-30
- Last updated by the study team
- 2025-05-31
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;
- age 18 to 80 years.
You may not qualify if…
- co-occurrence of other neurological disorders;
- implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);
- severe claustrophobia;
- intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);
- ongoing treatment with cholinergic drugs
Where it is running
- Oregon Health & Science University — Portland, Oregon, United States (enrolling)
- University of Washington — Seattle, Washington, United States (enrolling)
- Pacific Parkinson's Research Centre | University of British Columbia — Vancouver, British Columbia, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.